Welcome to our dedicated page for Kellanova SEC filings (Ticker: K), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kellanova (K) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including the disclosures surrounding its acquisition by a Mars-affiliated entity and the end of its life as a publicly traded company. While Kellanova is now a wholly owned subsidiary of Acquiror 10VB8, LLC, associated with Mars, its past filings remain an important record for understanding its capital structure, governance, and transaction history.
Key documents include multiple Form 8-K reports describing the Agreement and Plan of Merger with Acquiror 10VB8, LLC and Merger Sub 10VB8, LLC, the closing of the merger on December 11, 2025, and the resulting status of Kellanova as a wholly owned subsidiary. These 8-Ks also note that, following the merger, Kellanova’s common stock would be delisted from the New York Stock Exchange and would cease to be publicly traded.
A Form 25 filed by the New York Stock Exchange on December 11, 2025, relates to the removal from listing and registration of Kellanova’s common stock and certain senior notes, while a Form 15 filed on December 22, 2025, certifies the termination of registration of the common stock and various series of senior notes under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of related reporting obligations. Earlier 8-K filings also cover antitrust review milestones for the Mars transaction and periodic financial results announcements.
On Stock Titan, these filings are updated from the SEC’s EDGAR system and paired with AI-powered summaries that explain the purpose and implications of each document in plain language. Users can quickly see how Kellanova’s obligations under its senior notes, credit facilities, and private placement agreements were addressed in connection with the merger, and how the delisting and deregistration process unfolded. For investors researching historical CPG transactions, capital markets activity, or the path from public listing to acquisition, this archive offers a structured view of Kellanova’s regulatory footprint.
Kellanova (K) insider filing shows the W.K. Kellogg Foundation Trust sold 114,583 shares of K common stock on 08/14/2025 at a reported price of $80.0734 per share, leaving the Trust with 45,326,620 shares after the transaction. The filing identifies the Trust as a reporting person with the Foundation as sole beneficiary and lists trustees and Northern Trust Company acting as corporate trustee. The sale was made pursuant to trading instructions dated May 7, 2024 that are intended to comply with Rule 10b5-1(c).
Northern Trust Corporation reports beneficial ownership of 49,661,119 shares of Kellanova common stock, representing 14.3% of the class. The holding is reported as a mix of 3,331,001 shares with sole voting power and 46,327,324 shares with shared voting power; sole dispositive power is 3,267,978 and shared dispositive power is 46,358,785. The filing is a Schedule 13G, and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
The Northern Trust Company is identified as the relevant subsidiary related to these holdings. The statement discloses material ownership levels and the allocation of voting and dispositive powers without indicating any intent to alter corporate control.
The W.K. Kellogg Foundation Trust reported a sale of 114,583 shares of Kellanova common stock on 08/07/2025 at an aggregate price of $79.97 per share. After the reported transaction, the Trust and related Foundation beneficially owned 45,441,203 shares.
The filing identifies the Trust as the reporting person with trustees named and the W.K. Kellogg Foundation as sole beneficiary. The sale was executed pursuant to trading instructions given on May 7, 2024 that are intended to comply with Rule 10b5-1(c), and the Form 4 discloses the transaction and resulting holdings.
Kellanova (K) Form 144 discloses that long-time shareholder W.K. Kellogg Foundation Trust plans to sell an additional 458,332 common shares through BofA Securities on or after 08-07-2025. At the recent market price used in the filing, the block is valued at $36.65 million.
The Trust has already sold 12 identical blocks of 114,583 shares between 05-07-2025 and 07-28-2025, totaling roughly 1.375 million shares and ≈$111 million in gross proceeds. Including the new notice, sales over the rolling three-month window would reach ≈1.83 million shares, or ≈0.53 % of Kellanova’s 345.2 million shares outstanding. The Trust acquired the stock via gifts and bequests dating back to 1970.
No officers or directors are named; therefore the filing reflects non-insider, charitable trust selling. While the percentage is modest, continued weekly liquidity events could create a short-term supply overhang and may be interpreted as incremental selling pressure.
Kellanova (K) – Form 4 insider transaction
On 07/28/2025 the W.K. Kellogg Foundation Trust, a designated 10 % owner, sold 114,583 common shares of Kellanova at an average price of $79.7883, raising about $9.1 million. After the sale the Trust still controls 45,555,786 shares, so the disposition reduced its position by roughly 0.25 %. The trade was executed under a Rule 10b5-1 plan adopted 05/07/2024, implying it was pre-programmed rather than opportunistic.
No derivative securities were reported and no other insiders filed concurrent transactions. Given the Trust’s large residual stake, the sale appears routine portfolio management and does not meaningfully alter Kellanova’s insider ownership profile.
FAQ
What is the current stock price of Kellanova (K)?
What is the market cap of Kellanova (K)?
